Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.

Journal of cancer research and clinical oncology - 1 May 2010

Gangwar Ruchika, Mandhani Anil, Mittal Rama Devi

Abstract excerpt

PURPOSE: To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility. MATERIALS AND METHODS: Genotyping was performed in 208 BC patients and 245 controls by PCR-RFLP method. RESULTS: XPC PAT +/+ genotype was associated with elevated risk of BC (p = 0.021, OR = 2.49). XPC Lys939Gln AC + CC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to BCG Vaccine
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to DNA-Binding Proteins

Share to Polymorphism, Genetic

Share to Risk Factors

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 19924443
DOI: 10.1007/s00432-009-0717-y

Genes

XPC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.PMID 19924443Read ↗

XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.Semantic proximity Read ↗

Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.Semantic proximity Read ↗

XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.Semantic proximity Read ↗

An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.Semantic proximity Read ↗

Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.Semantic proximity Read ↗

The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.Semantic proximity Read ↗

Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients.Semantic proximity Read ↗

XPC as breast cancer susceptibility gene: evidence from genetic profiling, statistical inferences and protein structural analysis.Semantic proximity Read ↗

Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer.Semantic proximity Read ↗

Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.Semantic proximity Read ↗

Associations between XPC polymorphisms and risk of cancers: A meta-analysis.Semantic proximity Read ↗

Current evidences on XPC polymorphisms and breast cancer susceptibility: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.